DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Fibroblast Growth Factor 2: An Epithelial Ductal Cell Growth Inhibitor That Drops Out in Breast Cancer
Annual rept. 15 Sep 2009-14 Sep 2010
CALIFORNIA UNIV SAN DIEGO LA JOLLA
Pagination or Media Count:
The overall objective of this work is to establish whether the growth factor called FGF merits investigation as a drug development target in a breast cancer therapeutic drug discovery program. We are now questioning the idea that FGF2 is involved in the dysinhibition model of breast cancer progression. If so the better approach would be to create FGF2 antagonists. To meet the overall idea, we are measuring the natural onset and progression of cancer in a mouse model of spontaneous mammary tumor development. We show that in a new line of PyVT mice that are cancer prone and lack one of the presumed regulators of tumor growth, FGF2 have altered tumor development kinetics.
APPROVED FOR PUBLIC RELEASE